Welcome to our dedicated page for Rani Therapeutics Holdings SEC filings (Ticker: RANI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rani Therapeutics Holdings, Inc. filings document the regulatory record of a clinical-stage biotherapeutics company developing oral delivery technology for biologics and drugs. Form 8-K reports include quarterly and annual financial results, corporate updates, clinical and preclinical program disclosures, collaboration and license matters, and material agreements affecting the company’s operations and strategy.
The filing record also covers capital-structure activity involving Class A common stock, common warrants and pre-funded warrants, as well as Nasdaq continued-listing compliance notices. Proxy materials describe annual meeting matters, board elections, auditor ratification, governance procedures and stockholder voting mechanics for RANI’s public-company structure.
Rani Therapeutics Holdings director Jean Luc Butel received a grant of stock options covering 123,600 shares of Class A common stock. The options have an exercise price of $0.9515 per share and expire on May 27, 2036.
The options were awarded as compensation, not purchased in the open market. According to the award terms, the options vest in full on the first anniversary of the May 28, 2026 grant date, provided the director maintains Continuous Service. They may vest earlier if the company holds its next annual stockholder meeting or undergoes a Change in Control while the director remains in service.
Rani Therapeutics director Bailey Vasudev Jaiprakash received a stock option grant covering 123,600 shares of Class A common stock. The option was awarded on May 28, 2026 at an exercise price of $0.9515 per share and is held directly.
The option vests in full on the first anniversary of the grant date, subject to the director’s continuous service under the company’s 2021 Equity Incentive Plan. Vesting can occur earlier if Rani Therapeutics holds its next annual stockholder meeting or if a Change in Control occurs, in each case only if continuous service requirements are met. After this grant, the director holds 123,600 derivative securities related to this option.
Rani Therapeutics Holdings director Dennis A. Ausiello received a grant of stock options covering 123,600 shares of Class A common stock. The options have an exercise price of $0.9515 per share and expire on May 27, 2036. This is a compensation-related award rather than an open-market purchase.
The options vest in full on the first anniversary of the grant date, subject to Dr. Ausiello’s continuous service. Vesting can occur earlier if either the company’s next annual stockholder meeting or a Change in Control happens while he remains in continuous service. Following this grant, he holds options for 123,600 shares directly.
Rani Therapeutics Holdings, Inc. held its annual stockholder meeting on May 28, 2026. Stockholders voted together as a single class, with one vote per share of both Class A and Class B common stock. As of April 2, 2026, there were 99,812,515 Class A shares and 23,970,359 Class B shares outstanding and entitled to vote.
All seven director nominees, including Talat Imran, Mir Imran, and the other board members listed, were elected to serve until the 2027 annual meeting or until successors are elected and qualified. Stockholders also ratified the appointment of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Samsara BioCapital funds and Dr. Srinivas Akkaraju filed an amended Schedule 13D to update their ownership in Rani Therapeutics Holdings’ Class A common stock following a May 2026 financing.
On May 26, 2026, Samsara BioCapital, L.P. purchased 934,580 shares and Samsara Opportunity Fund, L.P. purchased 934,579 shares at $1.07 per share in a registered direct offering for an aggregate $2 million, funded from working capital. After giving effect to shares outstanding and securities issuable within 60 days, Dr. Akkaraju is reported as beneficially owning 11,322,961 shares, representing 9.99% of the Class A common stock, subject to warrant Beneficial Ownership Blockers that limit exercises above this threshold.
Rani Therapeutics Holdings, Inc. entered into a securities purchase agreement with institutional investors to conduct a registered offering of equity. The deal covers 12,476,637 shares of Class A common stock at $1.07 per share and pre-funded warrants to purchase 6,214,953 shares at an exercise price of $0.0001 per share, sold at $1.0699 per warrant.
The transaction is expected to generate approximately $20.0 million in gross proceeds before fees, with a 6.0% cash fee payable to the placement agents. Closing is expected on or about May 27, 2026, subject to customary conditions.
Rani agreed to a 90-day restriction on most new equity issuances and a nine-month restriction on new variable rate transactions, while directors, officers and certain stockholders signed 60-day lock-up agreements limiting sales of Rani securities.
Rani Therapeutics is offering 12,476,637 shares of Class A common stock and pre-funded warrants to purchase 6,214,953 shares in a registered direct offering at an offering price of $1.07 per share (pre-funded warrants priced at $1.0699). The gross proceeds from the offering are approximately $19.99 million and estimated net proceeds to the company are approximately $18.4 million.
The pre-funded warrants have an exercise price of $0.0001, are immediately exercisable and include ownership caps (default 4.99%, electable to 9.99% with notice). Placement agents are H.C. Wainwright & Co. and Chardan Capital Markets; placement agent fees equal 6.0% (approximately $1.2 million). Net proceeds will be used to purchase newly issued LLC Interests from Rani LLC and for working capital and general corporate purposes.
Rani Therapeutics Holdings, Inc. reported higher contract revenue and a smaller overall loss for the three months ended March 31, 2026, while remaining a clinical‑stage company with no product sales yet. Contract revenue rose to $1.7 million, primarily from its Chugai collaboration, compared with $0.2 million a year earlier.
Total operating expenses fell to $10.0 million from $12.2 million, as both research and development and general and administrative costs declined, helped by lower compensation expense. Net loss narrowed to $8.0 million from $12.7 million, with net loss attributable to Rani essentially flat at about $7.0 million, or $(0.04) per Class A share versus $(0.22).
Rani ended March 31, 2026 with $43.4 million in cash, cash equivalents, and marketable securities and total assets of $51.9 million. Management believes this liquidity will fund operations for at least twelve months from issuance of these financial statements as it advances its RaniPill oral biologics platform, including the RT‑114 Phase 1 obesity trial with ProGen and the hemophilia collaboration with Chugai.
Rani Therapeutics Holdings, Inc. reported first quarter 2026 results, received a Nasdaq minimum bid-price deficiency notice, and announced a planned Chief Financial Officer transition. Contract revenue rose to $1.7 million from $0.2 million, while research and development and general and administrative expenses declined year over year.
The company recorded a net loss of $8.0 million versus $12.7 million a year earlier and ended March 31, 2026 with $43.4 million in cash, cash equivalents and marketable securities, which it expects to fund operations into the fourth quarter of 2027. Nasdaq notified Rani that its shares failed to meet the $1.00 Minimum Bid Price Requirement for 30 consecutive business days, triggering a 180‑day cure period to November 9, 2026, with potential additional time if it moves to The Nasdaq Capital Market and, if needed, effects a reverse stock split. CFO Svai Sanford will resign following appointment of a successor and will receive nine months of base salary, COBRA premiums, and accelerated vesting of unvested equity under a separation agreement.
Rani Therapeutics Holdings, Inc. filing amends a previously reported Schedule 13G to show SymBiosis Capital Partners, LLC beneficially owns 4,433,620 shares of Class A Common Stock, representing 4.4% of the class. The filing lists sole voting and dispositive power over 4,433,620 shares. The amendment is signed by the reporting firm's Managing Partner on 05/15/2026.